Welcome to the e-CCO Library!

P735 Comparative assessment of probiotics and standard therapies for mild to moderate ulcerative colitis: A systematic review and network meta-analysis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

P. Paschos1, A. Katsoula2, K. Malandris2, M. Sarigianni2, E. Athanasiadou2, A. Koukoufiki2, O. Giouleme3, A. Tsapas2

Created: Thursday, 30 January 2020, 10:12 AM
P735: Immunogenicity differences between anti-TNF drugs
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. M. Gómez Espín*1, I. Nicolás de Prado1, C. Iniesta Navalón2, L. Rentero Redondo2, M. Gil Candel2, J. J. Martínez Crespo1

Created: Friday, 22 February 2019, 9:41 AM
P735: Incidence of venous thromboembolic complications in controlled trials of inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Vermeire1*, M. Crowther2, V. Pradhan3, A. Banerjee3, F. Cataldi4, K. Gorelick5

Created: Thursday, 21 February 2019, 9:14 AM
P735: Indirect burden of patients with moderate inflammatory bowel disease in Uppsala County Council, Sweden: a retrospective study using real-world data
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Hellström P.M.*1, Stålhammar J.2, Beydogan H.3, Huetson P.3, Skup M.4, Agréus L.5

Created: Wednesday, 20 February 2019, 10:36 AM
P735: Real-life experience with the use of Tofacitinib in Colombian patients with moderate to severe Ulcerative Colitis: a descriptive study.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Parra Izquierdo, L.V.(1)*;Frías-Ordoñez, J.(2); Márquez, J.R.(3);Juliao-Baños , F.(4);Galindo, P.(5);Cuadros, C.(6);Rojas, C.(7);Rojas, N.(7);Ardila, O.(8);Tovar-Fierro , G.(9);García-Duperly, R.(10);Gil Parada, F.L.(11);Imbeth Acosta, P.L.(12);Puentes, F.E.(13);Galiano de Sánchez, M.T.(14);Hani de Ardila, A.(15); Flórez-Sarmiento, C.(1);
Created: Friday, 14 July 2023, 11:12 AM
P736 Utility of infliximab serum concentration in inflammatory bowel disease treatment in real world practice at Hospital Universitario de Canarias
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Carrillo Palau1, I. Alonso-Abreu1, L. Ramos-Lopez1, G.N. Fernando2, N. Hernandez Alvarez-Buylla1, A. Hernandez-Perez1, S. Medina-Chico1, E. Quintero1

Created: Thursday, 30 January 2020, 10:12 AM
P736: Characteristics of polymeric formula and mode of delivery of exclusive enteral nutrition have no effect on disease outcome and weight gain in children with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

I. Hojsak*1, I. Trivic1, S. Sila1, K. Matic2, Z. Misak1, S. Kolacek1

Created: Friday, 22 February 2019, 9:41 AM
P736: Factors associated with partial Mayo Clinic Score over time in patients with Ulcerative Colitis treated with filgotinib in the phase 2b/3 SELECTION trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Peyrin-Biroulet, L.(1)*;Louis , E.(2);Hisamatsu, T.(3);Jamoul, C.(4);Santermans, E.(4);Harris , K.(5);de Haas, A.(6);Oortwijn , A.(7);Feagan , B.(8);
Created: Friday, 14 July 2023, 11:12 AM
P736: Point-of-care infliximab quantification in inflammatory bowel disease in daily practice
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.P. Costa Santos*, C. Palmela, C. Gouveia, C. Fidalgo, L. Glória, M. Cravo, J. Torres

Created: Thursday, 21 February 2019, 9:14 AM
P736: Psychological impact of inflammatory bowel disease: differences by gender and age. The ENMENTE Project
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Gobbo Montoya M.1, Marín-Jiménez I.2, Panadero A.3, Modino Y.4, Cañas M.5, Guardiola J.6, Cea-Calvo L.7, Juliá B.7, Romero C.7, Carmona L.8, Barreiro-de Acosta M.*9

Created: Wednesday, 20 February 2019, 10:36 AM
P737 Ustekinumab induction effectiveness in Crohn’s disease in a real-life cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Sánchez Rodríguez, F. Mesonero Gismero, A. López sanroman

Created: Thursday, 30 January 2020, 10:12 AM
P737: Early life microbial exposure, lifestyle and comorbidity as risk factors for microscopic colitis: a case-control study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Verhaegh B.P.M.*1,2, Jonkers D.M.A.E.1,2, Pierik M.J.1, Masclee A.A.M.1,2, Goudkade D.3

Created: Wednesday, 20 February 2019, 10:36 AM
P737: Intensification with intravenous ustekinumab in refractory Crohn´s disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Arroyo Argüelles, J.M.(1);Suárez Ferrer, C.(2)*;Rueda García, J.L.(2);Martín-Arranz, E.(2);Poza Cordón, J.(2);Sánchez-Azofra, M.(2);García-Ramírez, L.(3);Martin-Arranz, M.D.(4);
Created: Friday, 14 July 2023, 11:12 AM
P737: SPOSIB SB2: A Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab Biosimilar SB2 (Flixabi®): interim analysis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

F. S. Macaluso*1, M. Cappello2, E. Giuffrida2, W. Fries3, A. Centritto3, A. C. Privitera4, G. Inserra5, R. Vassallo6, A. Magnano7, E. Vinci7, S. Garufi8, M. Ventimiglia1, S. Renna1, R. Orlando1, G. Rizzuto1, M. Cottone1, A. Orlando1

Created: Friday, 22 February 2019, 9:41 AM
P737: The use of infliximab therapeutic drug monitoring in virtual biologics clinic for inflammatory bowel disease (IBD) leads to clinically durable results
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Sagar1, M. Lenti1, T. Clark1, H. Rafferty1, D. Gracie1, A. Ford1, A. O'Connor1, J. Hamlin1, T. Ahmad2, C. Selinger1*

Created: Thursday, 21 February 2019, 9:14 AM
P738 Real world outcomes on the efficacy and safety of combination of biologic and immunosuppressive therapy in liver transplant recipients with inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.L. Chatzinikolaou1, N. O’Shea1, G. Erian1, A. Koutsoumpas1, J. Ryan2, M. Hamilton1, C. Murray1

Created: Thursday, 30 January 2020, 10:12 AM
P738: Assessing aCCess to investigations in IBD (ACCID) – results from an international inflammatory bowel disease survey
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ding N.S.*1,2,3, Yazdanian B.4, Bettenworth D.5, Cleynen I.6, Yassin N.A.2, Armuzzi A.7, Ferrante M.8, Zagorowicz E.S.9, Mansfield J.10, Gisbert J.11, Raine T.4

Created: Wednesday, 20 February 2019, 10:36 AM
P738: Surgery for Crohn's Disease: Results from a Spanish cohort with 15 years of follow-up
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Elosua Gonzalez, A.(1)*;Rubio, S.(2);Irisarri, R.(2);Campillo, A.(3);Nantes, Ó.(2);Vicuña, M.(2);Angós, R.(4);Zozaya, J.M.(2);Rodríguez, C.(2);
Created: Friday, 14 July 2023, 11:12 AM
P738: Sustained clinical remission with vedolizumab in Moderate-to-Severe Crohn’s disease: A GEMINI 2 post hoc analysis of Week 14 remitters
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Hardi1, B. Bokemeyer2, W. Sandborn3, W. Reinisch4, I. Shafran5, A. Stallmach6, R. Ehehalt7, P. Geransar8*, J.M. Khalid9, D. Tudor10, S. Schreiber11

Created: Thursday, 21 February 2019, 9:14 AM
P738: The budget impact of early dose optimisation with golimumab in ulcerative colitis in the UK
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Black*1, A. Hirst2, A. Brandtmüller3, S. Kachroo1, A. Puenpatom3

Created: Friday, 22 February 2019, 9:41 AM